COGNITION THERAPEUTICS INC (CGTX)
$1.00-$0.06 (-5.49%) Today
Latest CGTX Insider Trades
John Brendan Doyle - OfficerOpen-market purchase$11K
John Brendan Doyle - Officer
Brett P. Monia - Director
Peggy Wallace - DirectorCognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 5 | 125,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
20 Form 4 filings on record, the earliest from Jun 18, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jack A. Khattar - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Brett P. Monia - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Peggy Wallace - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Ellen B. Richstone - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Aaron G.L. Fletcher - Director | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| John Brendan Doyle - Officer | Tax withholding / forfeiture | Common Stock | 8,567 | $1.28 | $11K | |
| John Brendan Doyle - Officer | Open-market purchase | Common Stock | 10,000 | $1.13 | $11K | |
| Lisa Ricciardi - Officer | Open-market purchase | Common Stock | 9,175 | $1.10 | $10K | |
| Anthony Caggiano - Officer | Open-market purchase | Common Stock | 10,000 | $1.11 | $11K | |
| Lisa Ricciardi - Officer | Tax withholding / forfeiture | Common Stock | 5,850 | $1.12 | $7K | |
| John Brendan Doyle - Officer | Tax withholding / forfeiture | Common Stock | 1,560 | $1.12 | $2K | |
| Anthony Caggiano - Officer | Tax withholding / forfeiture | Common Stock | 4,680 | $1.12 | $5K | |
| Lisa Ricciardi - Officer | Grant or award | Common Stock | 800,000 | $0.00 | - | |
| Lisa Ricciardi - Officer | Tax withholding / forfeiture | Common Stock | 26,036 | $1.12 | $29K | |
| Lisa Ricciardi - Officer | Tax withholding / forfeiture | Common Stock | 51,704 | $1.03 | $53K | |
| John Brendan Doyle - Officer | Grant or award | Common Stock | 200,000 | $0.00 | - | |
| John Brendan Doyle - Officer | Tax withholding / forfeiture | Common Stock | 26,921 | $1.03 | $28K | |
| Anthony Caggiano - Officer | Grant or award | Common Stock | 400,000 | $0.00 | - | |
| Anthony Caggiano - Officer | Tax withholding / forfeiture | Common Stock | 11,488 | $1.12 | $13K | |
| Anthony Caggiano - Officer | Tax withholding / forfeiture | Common Stock | 26,919 | $1.03 | $28K | |
| Aaron G.L. Fletcher - Director | Option exercise | Common Stock | 7,729 | $0.84 | $6K | |
| Aaron G.L. Fletcher - Director | Option exercise | Stock Option (right to buy) | 7,729 | $0.00 | - | |
| Lisa Ricciardi - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Lisa Ricciardi - Officer | Tax withholding / forfeiture | Common Stock | 23,400 | $0.67 | $16K | |
| John Brendan Doyle - Officer | Grant or award | Common Stock | 30,000 | $0.00 | - | |
| John Brendan Doyle - Officer | Tax withholding / forfeiture | Common Stock | 9,360 | $0.67 | $6K | |
| Anthony Caggiano - Officer | Grant or award | Common Stock | 65,000 | $0.00 | - | |
| Anthony Caggiano - Officer | Tax withholding / forfeiture | Common Stock | 20,281 | $0.67 | $14K | |
| Ellen B. Richstone - Director | Grant or award | Common Stock | 34,000 | $0.00 | - |
COGNITION THERAPEUTICS INC (CGTX) had 5 insider filings in the last 90 days, with the most recent on 2026-06-22. The full record for CGTX runs to 20 Form 4 filings, the earliest from 2025-06-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CGTX were filed in the last 90 days. 3 purchases are on record for this company.
No insider sales of CGTX were filed in the last 90 days.
This page tracks CGTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CGTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
